This device evaluation, which has been recently published in our partner journal Pain Management, reviews five clinical trials and two real-world evidence studies that assessed the safety, tolerability and efficacy of Nerivio® in treating migraine attacks. Nerivio is a remote electrical neuromodulation (REN) device controlled by a smartphone application. It has been US FDA approved and European Conformity marked for the treatment of migraine with or without aura in people 12 years and older. Based on the findings of this review, Nerivio is safe, well-tolerated and effective in achieving sustained pain relief and pain freedom from 2 hours post-treatment and for at least 24 hours post-treatment. Additionally, it provides relief from other migraine-associated symptoms including nausea and/or vomiting, photophobia and phonophobia.
Nerivio® (by Theranica Bio-Electronics Ltd., Netanya, Israel) is a wireless, wearable, non-invasive, battery-operated, remote electrical neuromodulation (REN) device controlled by a smartphone application. It is US FDA authorized for the acute treatment of migraine with or without aura in people 12 years and older in the USA and European Conformity (CE) marked for the same indication in the EU. The American Headache Society Consensus Statement recommends Nerivio as a tier 2 treatment for migraines. This review summarizes a series of five independent clinical trials and two real-world evidence studies that established safety, tolerability and efficacy of Nerivio in treating migraine attacks. It further provides up-to-date practical information on device usability. Based on findings of this review, Nerivio offers a safe and effective non-pharmacological alternative for acute treatment in patients with chronic (and non-chronic) migraine.
Nerivio® is a Bluetooth-enabled device controlled via smartphones for the treatment of migraine attacks. The device is placed on the arm and kept in place with an armband, delivering non-painful electrical stimulation that in turn activates signals in the brain to release substances that help break pain. The device is cleared by the US FDA for the acute treatment of migraine in people 12 years or older with episodic or chronic migraine. This review provides a summary of several clinical trials and real-world evidence studies that helped show the safety, tolerability and efficacy of Nerivio as a migraine treatment. Based on these findings, Nerivio can offer a safe, well tolerated non-medication option for patients with migraine.
Read the full paper titled ‘Nerivio® remote electrical neuromodulation for acute treatment of chronic migraine’ here >>>
Meet the authors
Dr Hida Nierenburg is the director of headache medicine at Nuvance Health. She provides care to adults with headaches and facial pain. She is also passionate about bringing awareness for migraine and other disabling headaches to other clinicians in the region and to raise community awareness in order to minimize the burden of disability migraines can bring. She takes time to educate her patients about headaches to help them understand the illness.
Dr Nierenburg is double board certified in neurology and headache medicine. Dr. Nierenburg’s areas of expertise include treatment for migraines and other primary headaches which can include oral medications, Botox injections, nerve blocks and some non-medication options. Dr Nierenburg prides herself in education about headaches which is something she does with patients in order to help them understand the illness.
Dr Nierenburg completed her fellowship in headaches at Mount Sinai Roosevelt Headache Institute in New York City, and her residency in neurology at Georgetown University Hospital in Washington D.C. Dr Nierenburg is at the forefront of migraine treatment including advances with infusion therapy and electroceuticals and other types of non-medication options to treat migraine.
In her free time, Dr Nierenburg enjoys hiking, exercising, and exploring new restaurants.
Dr Alit Stark-Inbar is the Vice President of Medical Information at Theranica (NJ, USA). She connects between science, technology and clinical needs. She strives to make a significant impact in the research, development and clinical implementation of effective neurotech solutions that address unmet medical challenges, to improve people’s health and quality of life. Dr Stark-Inbar received her PhD in computational neuroscience from the Hebrew University of Jerusalem and completed her neuroscience postdoctoral fellowship at the University of California, Berkeley. Prior to joining Theranica, she served as the Director of Research and Chief Scientist Officer in other neurotech companies. She led neuroscientific studies in headache, movement disorders, psychiatric disorders and cognitive impairment, in addition to basic science studies involving healthy adults. Her research and development activities include new technologies in the fields of digital health, mobile health, and medical devices, using behavioral methods, virtual reality, peripheral stimulation, brain stimulation and imaging.